001     163952
005     20240315115353.0
024 7 _ |a pmc:PMC9321158
|2 pmc
024 7 _ |a 10.1002/mds.29005
|2 doi
024 7 _ |a pmid:35445419
|2 pmid
024 7 _ |a 0885-3185
|2 ISSN
024 7 _ |a 1531-8257
|2 ISSN
024 7 _ |a altmetric:127044895
|2 altmetric
037 _ _ |a DZNE-2022-00626
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Wenning, Gregor K
|b 0
245 _ _ |a The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy.
260 _ _ |a New York, NY
|c 2022
|b Wiley
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1655991523_2096
|2 PUB:(DE-HGF)
|x Review Article
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a (CC BY)
520 _ _ |a The second consensus criteria for the diagnosis of multiple system atrophy (MSA) are widely recognized as the reference standard for clinical research, but lack sensitivity to diagnose the disease at early stages.To develop novel Movement Disorder Society (MDS) criteria for MSA diagnosis using an evidence-based and consensus-based methodology.We identified shortcomings of the second consensus criteria for MSA diagnosis and conducted a systematic literature review to answer predefined questions on clinical presentation and diagnostic tools relevant for MSA diagnosis. The criteria were developed and later optimized using two Delphi rounds within the MSA Criteria Revision Task Force, a survey for MDS membership, and a virtual Consensus Conference.The criteria for neuropathologically established MSA remain unchanged. For a clinical MSA diagnosis a new category of clinically established MSA is introduced, aiming for maximum specificity with acceptable sensitivity. A category of clinically probable MSA is defined to enhance sensitivity while maintaining specificity. A research category of possible prodromal MSA is designed to capture patients in the earliest stages when symptoms and signs are present, but do not meet the threshold for clinically established or clinically probable MSA. Brain magnetic resonance imaging markers suggestive of MSA are required for the diagnosis of clinically established MSA. The number of research biomarkers that support all clinical diagnostic categories will likely grow.This set of MDS MSA diagnostic criteria aims at improving the diagnostic accuracy, particularly in early disease stages. It requires validation in a prospective clinical and a clinicopathological study. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a diagnosis
|2 Other
650 _ 7 |a diagnostic criteria
|2 Other
650 _ 7 |a multiple system atrophy
|2 Other
650 _ 2 |a Brain: pathology
|2 MeSH
650 _ 2 |a Consensus
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Magnetic Resonance Imaging
|2 MeSH
650 _ 2 |a Multiple System Atrophy: diagnosis
|2 MeSH
650 _ 2 |a Multiple System Atrophy: pathology
|2 MeSH
650 _ 2 |a Prospective Studies
|2 MeSH
700 1 _ |a Stankovic, Iva
|0 0000-0003-1484-4717
|b 1
700 1 _ |a Vignatelli, Luca
|0 0000-0002-9051-7091
|b 2
700 1 _ |a Fanciulli, Alessandra
|0 0000-0002-2854-4179
|b 3
700 1 _ |a Calandra-Buonaura, Giovanna
|b 4
700 1 _ |a Seppi, Klaus
|0 0000-0001-6503-1455
|b 5
700 1 _ |a Palma, Jose-Alberto
|0 0000-0002-1345-6774
|b 6
700 1 _ |a Meissner, Wassilios G
|0 0000-0003-2172-7527
|b 7
700 1 _ |a Krismer, Florian
|0 0000-0002-4493-5073
|b 8
700 1 _ |a Berg, Daniela
|0 P:(DE-2719)2000059
|b 9
|u dzne
700 1 _ |a Cortelli, Pietro
|0 0000-0002-3633-8818
|b 10
700 1 _ |a Freeman, Roy
|b 11
700 1 _ |a Halliday, Glenda
|0 0000-0003-0422-8398
|b 12
700 1 _ |a Höglinger, Günter
|0 P:(DE-2719)2811373
|b 13
|u dzne
700 1 _ |a Lang, Anthony
|b 14
700 1 _ |a Ling, Helen
|0 0000-0003-1532-3526
|b 15
700 1 _ |a Litvan, Irene
|b 16
700 1 _ |a Low, Phillip
|b 17
700 1 _ |a Miki, Yasuo
|b 18
700 1 _ |a Panicker, Jalesh
|b 19
700 1 _ |a Pellecchia, Maria Teresa
|b 20
700 1 _ |a Quinn, Niall
|b 21
700 1 _ |a Sakakibara, Ryuji
|0 0000-0002-5803-169X
|b 22
700 1 _ |a Stamelou, Maria
|0 0000-0003-1668-9925
|b 23
700 1 _ |a Tolosa, Eduardo
|b 24
700 1 _ |a Tsuji, Shoji
|b 25
700 1 _ |a Warner, Tom
|b 26
700 1 _ |a Poewe, Werner
|b 27
700 1 _ |a Kaufmann, Horacio
|0 0000-0002-1851-9981
|b 28
773 _ _ |a 10.1002/mds.29005
|g p. mds.29005
|0 PERI:(DE-600)2041249-6
|n 6
|p 1131-1148
|t Movement disorders
|v 37
|y 2022
|x 0885-3185
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/163952/files/DZNE-2022-00626.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/163952/files/DZNE-2022-00626.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:163952
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 9
|6 P:(DE-2719)2000059
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 13
|6 P:(DE-2719)2811373
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2022
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2022-11-11
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2022-11-11
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b MOVEMENT DISORD : 2021
|d 2022-11-11
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2021-01-30
|w ger
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-01-30
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-11
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2022-11-11
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b MOVEMENT DISORD : 2021
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-01-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2022-11-11
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2022-11-11
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-11
920 1 _ |0 I:(DE-2719)1111015
|k AG Höglinger 2
|l Coordinator of Clinical Parkinson Research
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1111015
980 1 _ |a FullTexts


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21